Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

Huageng Huang; Wei Zhang; Xinyi Deng; He Huang; Zhao Wang; Huangming Hong; Tongyu Lin

doi:10.1186/s40164-024-00510-w

Experimental Hematology & Oncology (Apr 2024)

Novel agents and regimens in relapsed or refractory peripheral T-cell lymphoma: latest updates from 2023 ASH annual meeting

Huageng Huang,
Wei Zhang,
Xinyi Deng,
He Huang,
Zhao Wang,
Huangming Hong,
Tongyu Lin

Affiliations

Huageng Huang: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
Wei Zhang: Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China
Xinyi Deng: Department of Dermatology, The First Affiliated Hospital of Guangzhou Medical University
He Huang: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
Zhao Wang: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center
Huangming Hong: Department of Medical Oncology, Senior Ward and Phase I Clinical Trial Ward, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China
Tongyu Lin: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center

DOI: https://doi.org/10.1186/s40164-024-00510-w
Journal volume & issue: Vol. 13, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of hematological malignancies with poor survival, while treatment options for relapsed or refractory (R/R) disease remain quite limited, with a median progression-free survival of only 3–4 months. Notably, the emergence of innovative therapeutic agents and regimens holds promise for durable responses and improved survival for patients with R/R PTCL. We summarize recent advances in the treatment of R/R PTCL from the 2023 ASH Annual Meeting, highlighting novel agents targeting EZH1/2, JAK1, PI3K, KIR3DL2, CD38/CD3xCD28, or CDK9, as well as therapeutic regimens in combination with stem cell transplantation, immunomodulators, epigenetic modifying agents, or CD30/CD16A bispecific antibodies.

Published in Experimental Hematology & Oncology

ISSN: 2162-3619 (Online)
Publisher: BMC
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the blood and blood-forming organs; Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://ehoonline.biomedcentral.com

About the journal

Abstract

Keywords